1DQ8 | B:537-585,B:704-865; C:537-585,C:704-865; D:537-585,D:704-864; A:537-585,A:704-862 | COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH HMG AND COA |
1DQ9 | C:537-585,C:704-866; A:537-585,A:704-865; D:537-585,D:704-865; B:537-585,B:704-864 | COMPLEX OF CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH HMG-COA |
1DQA | B:537-585,B:704-866; A:537-585,A:704-870; C:537-585,C:704-870; D:537-585,D:704-870 | COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH HMG, COA, AND NADP+ |
1HW8 | C:537-585,C:704-860; A:537-585,A:704-859; B:537-585,B:704-859; D:537-585,D:704-859 | COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH COMPACTIN (ALSO KNOWN AS MEVASTATIN) |
1HW9 | B:537-585,B:704-860; A:537-585,A:704-859; C:537-585,C:704-859; D:537-585,D:704-858 | COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH SIMVASTATIN |
1HWI | C:537-585,C:704-862; A:537-585,A:704-861; B:537-585,B:704-860; D:537-585,D:704-860 | COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH FLUVASTATIN |
1HWJ | A:537-585,A:704-860; B:537-585,B:704-860; C:537-585,C:704-859; D:537-585,D:704-859 | COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH CERIVASTATIN |
1HWK | A:537-585,A:704-860; C:537-585,C:704-860; B:537-585,B:704-859; D:537-585,D:704-859 | COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH ATORVASTATIN |
1HWL | B:537-585,B:704-860; C:537-585,C:704-860; D:537-585,D:704-860; A:537-585,A:704-859 | COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH ROSUVASTATIN (FORMALLY KNOWN AS ZD4522) |
2Q1L | A:537-585,A:704-861; B:537-585,B:704-861; C:537-585,C:704-860; D:537-585,D:704-859 | DESIGN AND SYNTHESIS OF PYRROLE-BASED, HEPATOSELECTIVE HMG-COA REDUCTASE INHIBITORS |
2Q6B | D:537-585,D:704-866; A:537-585,A:704-864; B:537-585,B:704-863; C:537-585,C:704-863 | DESIGN AND SYNTHESIS OF NOVEL, CONFORMATIONALLY RESTRICTED HMG-COA REDUCTASE INHIBITORS |
2Q6C | A:537-585,A:704-861; D:537-585,D:704-861; B:537-585,B:704-860; C:537-585,C:704-860 | DESIGN AND SYNTHESIS OF NOVEL, CONFORMATIONALLY RESTRICTED HMG-COA REDUCTASE INHIBITORS |
2R4F | A:537-585,A:704-860; B:537-585,B:704-860; C:537-585,C:704-860; D:537-585,D:704-860 | SUBSTITUTED PYRAZOLES AS HEPATSELECTIVE HMG-COA REDUCTASE INHIBITORS |
3BGL | A:537-585,A:704-861; B:537-585,B:704-861; C:537-585,C:704-860; D:537-585,D:704-859 | HEPATOSELECTIVITY OF STATINS: DESIGN AND SYNTHESIS OF 4-SULFAMOYL PYRROLES AS HMG-COA REDUCTASE INHIBITORS |
3CCT | A:537-585,A:704-861; B:537-585,B:704-861; C:537-585,C:704-860; D:537-585,D:704-859 | THERMODYNAMIC AND STRUCTURE GUIDED DESIGN OF STATIN HMG-COA REDUCTASE INHIBITORS |
3CCW | A:537-585,A:704-861; B:537-585,B:704-861; C:537-585,C:704-860; D:537-585,D:704-859 | THERMODYNAMIC AND STRUCTURE GUIDED DESIGN OF STATIN HMG-COA REDUCTASE INHIBITORS |
3CCZ | A:537-585,A:704-860; B:537-585,B:704-860; C:537-585,C:704-860; D:537-585,D:704-860 | THERMODYNAMIC AND STRUCTURE GUIDED DESIGN OF STATIN HMG-COA REDUCTASE INHIBITORS |
3CD0 | A:537-585,A:704-861; B:537-585,B:704-861; D:537-585,D:704-861; C:537-585,C:704-860 | THERMODYNAMIC AND STRUCTURE GUIDED DESIGN OF STATIN HMG-COA REDUCTASE INHIBITORS |
3CD5 | A:537-585,A:704-865; B:537-585,B:704-865; C:537-585,C:704-864; D:537-585,D:704-864 | THERMODYNAMIC AND STRUCTURE GUIDED DESIGN OF STATIN HMG-COA REDUCTASE INHIBITORS |
3CD7 | A:537-585,A:704-861; B:537-585,B:704-861; C:537-585,C:704-860; D:537-585,D:704-859 | THERMODYNAMIC AND STRUCTURE GUIDED DESIGN OF STATIN HMG-COA REDUCTASE INHIBITORS |
3CDA | A:537-585,A:704-862; B:537-585,B:704-861; C:537-585,C:704-860; D:537-585,D:704-859 | THERMODYNAMIC AND STRUCTURE GUIDED DESIGN OF STATIN HMG-COA REDUCTASE INHIBITORS |
3CDB | A:537-585,A:704-861; B:537-585,B:704-861; C:537-585,C:704-861; D:537-585,D:704-861 | THERMODYNAMIC AND STRUCTURE GUIDED DESIGN OF STATIN HMG-COA REDUCTASE INHIBITORS |